Increasing evidences have suggested that FOXA1 is overexpressed or amplified in lung cancer,37, 38 hepatocellular carcinoma,39 prostate cancer,40 glioma41 and esophageal adenocarcinoma.42 However, FOXA1s have a different role in breast cancer, maybe owing to the different dependence of estrogen receptor (data not shown), according to Toska’s reports.43, 44 In NSCLC,37 FOXA1 promoted proliferation, invasion and migration and reduce the chemosensitivity, which was consistent with our data shown in Figure 6, supporting that FOXA1 is the transcription factor of PLOD2. This evidence concerns the gene PLOD2 and breast cancer.